Cerbrospinal Fluid Markers in Multiple Sclerosis

  • A. R. Massaro
  • G. Carbone
Part of the NATO ASI Series book series (NSSA, volume 142)


We have been concerned for many years in research work regarding cere-brospinal fluid (CSF) markers of pathological events that happen during the course of multiple sclerosis (MS), and, in particular, during the acute phases of the disease (1,2,3). If one considers how difficult it is to obtain biopsy specimens of the central nervous system (CNS) in MS patients, and that autopsic specimens are not always indicative of the evolution of the lesion during the time, the study of the CSF proteins can provide us with an available tool for monitoring very important pathological events such as demyelination, immunitary reaction, glial activity, remyelination. All these events are of the greatest interest both for researches into the pathogenesis of the disease and for the clinical study of the patient.


Multiple Sclerosis Glial Fibrillary Acidic Protein Myelin Basic Protein Glial Activity Multiple Sclerosis Plaque 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. R. Massaro, Modifications of the CSF IgG concentrations in patients with MS treated with intrathecal steroids, J.Neurol., 219: 221 (1978).CrossRefGoogle Scholar
  2. 2.
    A. R. Massaro, F. Michetti, A. Laudisio, and P. Bergonzi, Myelin basic protein and S-100 antigen in CSF of patients with MS in the acute phase, Ital.J.Neurol.Sci., 6: 53 (1985)CrossRefGoogle Scholar
  3. 3.
    A. R. Massaro, M. Albrechtsen, and E. Bock, Determination of the neural cell adhesion molecule (N-CAM) in CSF from patients with MS, in: “Cellular and humoral components of CSF in MS”, J. Raus and A. Lowenthal, eds., Plenum, New York (1987).Google Scholar
  4. 4.
    J. N. Whitaker, Myelin encephalitogenic protein fragments in CSF of persons with MS, Neurology, 27: 991 (1977).Google Scholar
  5. 5.
    T. J. Cicero, W. Cowan, B. W. Moore, and V. Suntzeff, The cellular localization of two brain-specific proteins S-100 and 14.3.2, Brain Res., 18: 25 (1970).CrossRefGoogle Scholar
  6. 6.
    F. Michetti, A. R. Massaro, G. Russo, and G. Rigon, The S-100 antigen in CSF as a possible index of cell injury in the nervous system, J.Neurol.Sci., 44: 259 (1980).CrossRefGoogle Scholar
  7. 7.
    F. Michetti, A. R. Massaro, and M. Murazio, The nervous system-specific S-100 antigen in CSF of multiple sclerosis patients, Neurosci. Letters, 11: 171 (1979).CrossRefGoogle Scholar
  8. 8.
    A. Bignami, D. Dahl, and D. C. Rueger, GFAP in normal neural cells and in pathological conditions, in: “Advances in cellular neurobiology”, S. Fedoroff and L. Hertz, eds., Academic Press, New York, (1980).Google Scholar
  9. 9.
    J. R. Brown, G. W. Beebe, J. F. Kurtzke, The design of clinical studies to asses therapeutic efficacy in MS, Neurology, 29: 3 (1979).CrossRefGoogle Scholar
  10. 10.
    S. R. Cohen, G. M. McKhann, and M. Guarnieri, A RIA for myelin basic protein and its use for quantitative measurements, J.Neurochem., 25: 371 (1975).CrossRefGoogle Scholar
  11. 11.
    B. W. Moore, V. J. Perez, Complement fixation for antigens at a pico-gram level, J.Immunol., 96: 1000 (1966).Google Scholar
  12. 12.
    B. W. Moore, A soluble protein characteristic of the nervous system, Biochem.Biophys.Res.Commun., 19: 739 (1965).CrossRefGoogle Scholar
  13. 13.
    J. E. Zuckerman, H. R. Herschman, and L. Levine, Appearance of a brain specific antigen (the S-100 antigen) during human foetal development, J.Neurochem., 17: 247 (1970).CrossRefGoogle Scholar
  14. 14.
    M. Albrechtsen, A. R. Massaro, and E. Bock, Enzyme-linked immunosorbent assay for the human GFAP using mouse monoclonal antibody, J. Neurochem., 44: 560 (1985).CrossRefGoogle Scholar
  15. 15.
    D. Dahl and A. Bignami, GFAP from normal and gliosed human brain. Demonstration of multiple related polypeptides, Biochem.Biophys.Acta, 386: 41 (1975).CrossRefGoogle Scholar
  16. 16.
    M. Albrechtsen, A. C. von Gerstenberg, and E. Bock, Mouse monoclonal antibodies reacting with human brain GFAP, J.Neurochem., 42: 86 (1984).CrossRefGoogle Scholar
  17. 17.
    G. Mancini, A. O. Carbonara, and H. N. Hereman, Immunochemical quantitation of antigens by single radial immunodiffusion, Immunochem., 2: 235 (1965).CrossRefGoogle Scholar
  18. 18.
    S. K. Ludwin, J. C. Kosek, and L. F. Eng, The topographic distribution of S-100 and GFA proteins in the adult rat brain: immunohistochemical study using horseradish peroxidase labeled antibodies, J.Comp. Neurol., 165: 197 (1976).CrossRefGoogle Scholar
  19. 19.
    M. Kanamori, T. Endo, S. Shirakawa, M. Sakurai, and H. Hidaha, S-100 antigen in human T-lymphocytes, Biochem.Biophys.Res.Commun., 108: 1447 (1982).CrossRefGoogle Scholar
  20. 20.
    U. Traugott, E. L. Reinherz, and C. S. Raine, Multiple sclerosis: distribution of T cells, T cell subsets, and la-positive macrophages in lesions of different ages, J.Neuroimmunol., 4: 201 (1983).CrossRefGoogle Scholar
  21. 21.
    A. R. Massaro, G. Carbone, S. Sbriccoli, and G. Macchi, An immunoperox-idase study of GFAP and S-100 in multiple sclerosis brain, manuscript in preparation.Google Scholar
  22. 22.
    A. Fontana, F. Kristensen; R. Dubs, D. Gemsa, and E. Weber, Production of Prostaglandin-E and Interleukin-1 like factor by cultured astro-cytes and C6 glioma cells, J.Immunol., 129: 2413 (1982).Google Scholar
  23. 23.
    A. Fontana, R. Dubs, R. Merchant, S. Balsinger, and P. J. Grob, A new Limphokine: Part 1, J.Neuroimmunol., 2: 55 (1982).CrossRefGoogle Scholar
  24. 24.
    A. Fontana, U. Otz, A. L. de Weck, and P.J. Grob, A new Limphokine: Part 2, J.Neuroimmunol., 2: 73 (1982).CrossRefGoogle Scholar
  25. 25.
    W. W. Tourtellotte, On CSF IgG quotients in MS and other diseases: review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system, J.Neurol.Sci., 10: 279 (1970).CrossRefGoogle Scholar
  26. 26.
    W. W. Tourtellotte, CSF immunoglobulins and the central nervous system as an immunological organ particularly in MS and SSPE, in: “ARNMD Immunological Disorders of the Nervous System”, L. P. Rowland, ed., vol.49, William & Wilkins Co., Baltimore (1971).Google Scholar
  27. 27.
    M. Dubois-Dalcq, G. Shumacher, and E. K. Worthington, Immunoperoxidase studies on multiple sclerosis brain (abs), Neurology, 25: 496 (1975).Google Scholar
  28. 28.
    M. M. Eisiri, Immunoglobulin-containing cells in MS plaques, Lancet, 2: 478 (1977).CrossRefGoogle Scholar
  29. 29.
    G. Weissman and L. Thomas, The effect of corticosteroids upon connective tissue and lysosomes, Recent.Progr.Horm.Res., 20: 215 (1964).Google Scholar
  30. 30.
    W. T. Butler, Corticosteroids and immunoglobulin synthesis, Transplant. Proc., 7: 49 (1975).Google Scholar
  31. 31.
    A. R. Massaro, F. Michetti, and P. Bergonzi, Valutazione della proteina S-100 nel liquido cefalorachidiano di pazienti di sclerosi multipla in fase acuta sottoposti a terapia steroidea, in: “Riassunti del XXIII Congresso Nazionale della S.I.N.”, D. Mancia, M. Manfredi, G. A. Buscaino, eds., Parma (1983).Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • A. R. Massaro
    • 1
  • G. Carbone
    • 1
  1. 1.Department of NeurologyUniversità Cattolica S. CuoreRomaItaly

Personalised recommendations